|Systematic (IUPAC) name|
|CAS Registry Number|
|Molecular mass||398.496 g/mol|
|(what is this?)|
JWH-193 is a drug from the aminoalkylindole family which acts as a cannabinoid receptor agonist. It was invented by the pharmaceutical company Sanofi-Winthrop in the early 1990s. JWH-193 has a binding affinity at the CB1 receptor of 6nM, binding around seven times more tightly than the parent compound JWH-200, though with closer to twice the potency of JWH-200 in activity tests. A structural isomer of JWH-193 with the methyl group on the indole ring instead of the naphthoyl ring, was also found to be of similarly increased potency over JWH-200.
- Huffman JW, Padgett LW. Recent Developments in the Medicinal Chemistry of Cannabimimetic Indoles, Pyrroles and Indenes. Current Medicinal Chemistry, 2005; 12: 1395-1411.
- Eissenstat MA et al. (August 1995). "Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics". Journal of Medicinal Chemistry 38 (16): 3094–105. doi:10.1021/jm00016a013. PMID 7636873.
- Shim JY et al. (November 1998). "Three-dimensional quantitative structure-activity relationship study of the cannabimimetic (aminoalkyl)indoles using comparative molecular field analysis". Journal of Medicinal Chemistry 41 (23): 4521–32. doi:10.1021/jm980305c. PMID 9804691.
|This cannabinoid related article is a stub. You can help Wikipedia by expanding it.|